Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic HER2-Low Breast Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06551116
What this trial is testing

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine 200
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Large-scale testing (Phase 3)Looking for participantsNCT05904964
What this trial is testing

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Who this might be right for
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 288
Post-approval studies (Phase 4)Looking for participantsNCT07195344
What this trial is testing

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Who this might be right for
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud 210
Not applicableStudy completedNCT05217381
What this trial is testing

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Who this might be right for
Early Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
MedSIR 18,533
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07368543
What this trial is testing

Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Fudan University 216
Testing effectiveness (Phase 2)Study completedNCT06188559
What this trial is testing

BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eisai Inc. 56
Testing effectiveness (Phase 2)WithdrawnNCT05967286
What this trial is testing

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Active Not RecruitingNCT06561607
What this trial is testing

A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 542
Early research (Phase 1)Study completedNCT00821054
What this trial is testing

Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 24
Testing effectiveness (Phase 2)Study completedNCT02491892
What this trial is testing

Pertuzumab in Participants With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 79
Testing effectiveness (Phase 2)Study completedNCT00006228
What this trial is testing

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
National Cancer Institute (NCI) 37
Large-scale testing (Phase 3)Looking for participantsNCT06957886
What this trial is testing

BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Who this might be right for
HER2-low Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 566
Not applicableEnded earlyNCT05592483
What this trial is testing

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 78
Not applicableStudy completedNCT06168227
What this trial is testing

And Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 150
Testing effectiveness (Phase 2)UnknownNCT05018676
What this trial is testing

ARX788 in Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer With Low Expression of HER2
Fudan University 54
Testing effectiveness (Phase 2)Looking for participantsNCT05868226
What this trial is testing

PRE-ISPY Phase I/II Oncology Platform Program

Who this might be right for
HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more
QuantumLeap Healthcare Collaborative 280
Testing effectiveness (Phase 2)UnknownNCT04742153
What this trial is testing

MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Who this might be right for
Advanced or Metastatic Breast Cancer
Shanghai Miracogen Inc. 66
Not applicableStudy completedNCT07108595
What this trial is testing

Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 142
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Next Page